Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan

This study will collect safety information during routine medical care for children and adolescents in Japan who have been diagnosed with NTRK fusion-positive advanced or recurrent solid tumors who start treatment with repotrectinib. The study will describe how often side effects occur during treatment, with special attention to central nervous system disorders, interstitial lung disease, and fractures.

NCT Number	NCT07755826
Lead Sponsor	Bristol-Myers Squibb
Conditions	NTRK Fusion-positive Solid Tumors
Enrollment	20 participants
Start Date	2025-11-20
Primary Completion	2034-04-30 (estimated)
Study Completion	2034-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-10